Skip to main content
Premium Trial:

Request an Annual Quote

New England Biolabs NEBNext Enzymatic Methyl-seq

New England Biolabs has launched NEBNext Enzymatic Methyl-seq (EM-seq), an enzyme-based method for methylation sequencing that is an alternative to bisulfite sequencing. The EM-seq kit involves a two-step enzymatic conversion that first protects 5-methyl cytosine and 5-hydroxymethyl cytosine from deamination using TET2 and an oxidation enhancer, and then deaminates unmethylated cytosines, converting them to uracil. Because the process does not rely on chemical treatment, as with bisulfite conversion, the DNA is not damaged, according to the company. The kit includes the required reagents for EM-seq conversion and library preparation for sequencing on Illumina instruments.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.